Target intelligence / Profile preview

RNA, 7SK small nuclear pseudogene 216 (RN7SKP216)

Target: RN7SKP216
Molecular classification: Pseudogene, Non-coding RNA (if functional RNA is produced, which is rare for pseudogenes)

Overview

RN7SKP216 is a pseudogene related to the 7SK small nuclear RNA gene. Pseudogenes are DNA sequences derived from ancestral genes that have lost their protein-coding potential or function, often due to mutations. RN7SKP216 does not encode a functional molecule or serve in a well-established biological process[2]. In contrast, the canonical RN7SK gene produces an snRNA component of the 7SK snRNP complex, which regulates transcription elongation by interacting with positive transcription elongation factor b (P-TEFb) and is implicated in cell differentiation and immune response. No molecular function, therapeutic targeting, drug interaction, disease association, biomarker utility, or safety concerns are documented for RN7SKP216[2][3][5]. Note: If you are interested in a functional molecule/receptor, you may be seeking information about the canonical RN7SK small nuclear RNA, which is distinct from the pseudogene RN7SKP216[5].

Other names: RN7SKP216RNA, 7SK small nuclear pseudogene 216

Mechanism of action

None established, since RN7SKP216 is not a drug target.

Biological functions

None established for RN7SKP216. The canonical RN7SK gene (not the pseudogene) is involved in negative regulation of transcription elongation by RNA polymerase II as part of the 7SK small nuclear ribonucleoprotein complex[5].Pseudogenes are generally non-functional, though in rare cases they can regulate their parental gene or participate in non-coding RNA networks; no such function is documented for RN7SKP216[2][3].

Disease associations

None directly known for RN7SKP216.Canonical RN7SK (not the pseudogene) and its snRNA-derived fragments may have roles in immune function and have altered expression profiles in diseases such as multiple sclerosis and some cancers, but these do not pertain to the pseudogene RN7SKP216[1][4].RN7SKP216 is not documented as having a disease association or phenotype[2].

Safety considerations

None known. RN7SKP216 is not a therapeutic target and does not present known safety or therapeutic challenges.

Interacting drugs

None. No drugs are documented to interact with RN7SKP216 or its transcript.

Biomarkers

None. RN7SKP216 is not used as a biomarker for patient selection or efficacy monitoring.

Beyond the preview

Go deeper on RNA, 7SK small nuclear pseudogene 216 (RN7SKP216).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, 7SK small nuclear pseudogene 216 (RN7SKP216).

Explore the full profile